Lymphocyte trafficking using in situ hybridization and physioanatomy of the intestinal immune system after human small bowel transplantation.

PubWeight™: 0.78‹?›

🔗 View Article (PMC 2972728)

Published in Transplant Proc on June 01, 1992

Authors

K Nakamura1, M Nalesnik, S Todo, T Takenaka, A Yagihashi, Y Iwaki, K Abu-Elmagd, J Reyes, A Tzakis, V Warty

Author Affiliations

1: Department of Pathology, Pittsburgh Transplant Institute, Pennsylvania.

Articles by these authors

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Kidney transplantation under FK 506. JAMA (1990) 7.45

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol (1978) 6.88

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Effects of internal and external ionic environment on excitability of squid giant axon. A macromolecular approach. J Gen Physiol (1965) 3.95

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Transplantation of multiple abdominal viscera. JAMA (1989) 3.59

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46

An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med (1995) 3.42

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation (2002) 3.22

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

Equitable allocation of extrarenal organs: with special reference to the liver. Transplant Proc (1988) 2.85

Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75

The relationship of physical fitness to lipid and lipoprotein(a) levels in adolescents with IDDM. Diabetes Care (1993) 2.70

The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40

Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: a nation-wide sero-epidemiologic study. Int J Cancer (1982) 2.39

Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39

Liver transplantation across ABO blood groups. Surgery (1986) 2.39

Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol (1999) 2.37

Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37

Thoracic duct drainage before and after cadaveric kidney transplantation. Surg Gynecol Obstet (1979) 2.33

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33